Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
05 April 2022 - 6:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates to address serious diseases such as non-alcoholic
steatohepatitis (NASH) and obesity, today announced that management
will be presenting at the 21st Annual Needham Virtual Healthcare
Conference on Monday, April 11 at 2:15 p.m. ET.
A live audio webcast of the presentation will be available on
the investor relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcast will be archived
on Terns’ website for 30 days following the presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates to address serious diseases such as
NASH and obesity. Terns’ pipeline includes three clinical stage
development programs including an FXR agonist, a VAP-1 inhibitor
and a THR-β agonist, and a preclinical small-molecule GLP-1
receptor agonist program. For more information, please visit:
www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2024 to May 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2023 to May 2024